Figure 1From: Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic controlStudy design. * Glimepiride was initiated at 1Â mg/day, with the recommendation to uptitrate if fasting plasma glucose levels (assessed by home monitoring) were >110Â mg/dL, to 2Â mg/day at week 4, to 3Â mg/day at week 8, and to a maximum of 4Â mg/day at week 12. Uptitration can be withheld if it would place the patient at risk of hypoglycemia. Glimepiride dose can be downtitrated at any time to prevent recurrent hypoglycemia.Back to article page